MX2019003300A - Formulaciones de cisteamina y derivados de cisteamina. - Google Patents

Formulaciones de cisteamina y derivados de cisteamina.

Info

Publication number
MX2019003300A
MX2019003300A MX2019003300A MX2019003300A MX2019003300A MX 2019003300 A MX2019003300 A MX 2019003300A MX 2019003300 A MX2019003300 A MX 2019003300A MX 2019003300 A MX2019003300 A MX 2019003300A MX 2019003300 A MX2019003300 A MX 2019003300A
Authority
MX
Mexico
Prior art keywords
cysteamine
formulations
derivatives
neurodegenerative disorders
formulation consisting
Prior art date
Application number
MX2019003300A
Other languages
English (en)
Inventor
BARCHIELLI Marco
Colombo Paolo
Rossi Alessandra
Adorni Greta
Original Assignee
Recordati Ind Chimica E Farmaceutica Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ind Chimica E Farmaceutica Spa filed Critical Recordati Ind Chimica E Farmaceutica Spa
Publication of MX2019003300A publication Critical patent/MX2019003300A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describe la formulación de cisteamina oral que consiste en micropartículas de matriz lipídica en capas secas útiles para tratar la cistinosis y los trastornos neurodegenerativos.
MX2019003300A 2016-10-11 2017-10-10 Formulaciones de cisteamina y derivados de cisteamina. MX2019003300A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16193180.3A EP3308773A1 (en) 2016-10-11 2016-10-11 Formulations of cysteamine and cysteamine derivatives
PCT/EP2017/075801 WO2018069313A1 (en) 2016-10-11 2017-10-10 Formulations of cysteamine and cysteamine derivatives

Publications (1)

Publication Number Publication Date
MX2019003300A true MX2019003300A (es) 2019-05-22

Family

ID=57130210

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003300A MX2019003300A (es) 2016-10-11 2017-10-10 Formulaciones de cisteamina y derivados de cisteamina.

Country Status (13)

Country Link
US (1) US10813888B2 (es)
EP (2) EP3308773A1 (es)
JP (1) JP2019533668A (es)
KR (1) KR102321156B1 (es)
AU (1) AU2017341350B2 (es)
BR (1) BR112019006049A2 (es)
CA (1) CA3034554A1 (es)
CO (1) CO2019003858A2 (es)
EA (1) EA201990540A1 (es)
IL (1) IL264898B2 (es)
MX (1) MX2019003300A (es)
UA (1) UA123838C2 (es)
WO (1) WO2018069313A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
US7863288B2 (en) 2005-06-22 2011-01-04 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
AU2007210005C1 (en) 2006-01-27 2014-01-23 The Regents Of The University Of California Enterically coated cysteamine, cystamine and derivatives thereof
EP2172203A1 (en) 2008-09-17 2010-04-07 Giuliani S.P.A. Pharmaceutical composition for the treatment of gastrointestinal irritation disorders
EP2483761A4 (en) * 2009-09-08 2014-08-27 Qualcomm Inc TOUCH SCREEN WITH Z SPEED IMPROVEMENT
EP2968569A4 (en) * 2013-03-15 2016-11-02 Argenta Mfg Ltd COUGAR FORMULATION
TWI649100B (zh) * 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
CN103652366B (zh) 2013-09-17 2017-07-07 杭州康德权饲料有限公司 一种稳定微囊包膜半胱胺盐酸盐及其制备方法
WO2016005994A2 (en) * 2014-07-06 2016-01-14 Gattefosse India Pvt. Ltd. Pharmaceutical composition comprising solid dispersion of bcs class ii drugs with gelucires

Also Published As

Publication number Publication date
AU2017341350A1 (en) 2019-03-07
AU2017341350B2 (en) 2023-03-23
JP2019533668A (ja) 2019-11-21
IL264898A (en) 2019-05-30
EP3525761A1 (en) 2019-08-21
KR102321156B1 (ko) 2021-11-03
BR112019006049A2 (pt) 2019-06-25
CA3034554A1 (en) 2018-04-19
EP3308773A1 (en) 2018-04-18
WO2018069313A1 (en) 2018-04-19
CO2019003858A2 (es) 2019-04-30
KR20190057341A (ko) 2019-05-28
IL264898B1 (en) 2023-03-01
UA123838C2 (uk) 2021-06-09
IL264898B2 (en) 2023-07-01
US10813888B2 (en) 2020-10-27
EA201990540A1 (ru) 2019-08-30
US20190216741A1 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
EP3801625A4 (en) SILK-BASED PRODUCT FORMULATIONS AND USE PROCESSES
IL261756A (en) Preparations for the controlled release of cysteamine and systemic treatment of disorders sensitive to cysteamine
EP3585433A4 (en) THERAPEUTIC COMPOSITIONS AND ASSOCIATED METHODS FOR PHOTOIMMUNOTHERAPY
PH12019500494A1 (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
BR112019003579A2 (pt) Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
EP3328864A4 (en) COMPOUNDS AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF SOCIAL DISORDERS AND ADDICTION-RELATED DISORDERS
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
EP3846830A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES
EP3500291A4 (en) FORMULATIONS FOR THE ORAL ADMINISTRATION OF ACTIVE AGENTS
EP3554486A4 (en) PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF GLAUCOMA AND METHODS OF MAKING AND USING SAME
EP3641545A4 (en) COMPOSITIONS AND METHODS USING THEM FOR THE TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE
EP3720508A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF GENOMIC FOOTPRINT DISORDERS
EP3508193A4 (en) ORAL COMPOSITION AND ORAL PLAQUED DISPERSING AGENT
EP3554496A4 (en) METHODS AND COMPOSITIONS FOR TREATING PARKINSON&#39;S DISEASE
EP3532052A4 (en) DESIGN AND COMPOSITION OF CELL-STABILIZED PHARMACEUTICAL FORMULATIONS
EP3506947A4 (en) PHARMACEUTICAL FORMULATIONS OF REGADENOSONE
EP3261655A4 (en) Compositions and methods for the treatment of &#34;plaques and tangles&#34; in humans and animals
HK1259382A1 (zh) 藥物製劑及其用於治療色素性視網膜炎的用途
EP3628008A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER&#39;S DISEASE
EP3506906A4 (en) TOPICAL FENOLDOPAM FORMULATIONS FOR THE TREATMENT OF SKIN DISEASES
MX2019003300A (es) Formulaciones de cisteamina y derivados de cisteamina.
EP3554494A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION
EP3664800A4 (en) THERAPEUTIC FORMULATIONS AND USES THEREOF
EP3585411A4 (en) IL-22BP COMPOSITIONS AND METHODS OF TREATMENT OF DISEASES THEREOF